Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label study of olaparib versus liposomal doxorubicin in BRCA-associated recurrent ovarian cancer
2007-007622-22Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2008
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of olaparib and pegylated liposomal doxorubicin in ovarian cancer (3 arms), sponsored by AstraZeneca. Primary endpoint: Progression-free survival. Started Feb 2008; status: completed.
02
Drugs
olaparibpegylated liposomal doxorubicin
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2007-007622-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007622-22.